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Abstract Inflammatory mediators such as prostaglandin E 2 
(PGE2) and interleukin-I (IL-1) induce angiogenesis by yet unde- 
fined mechanisms. We demonstrate that PGE 2 and IL-1 induces 
the expression of vascular endothelial growth factor (VEGF), a 
selective angiogenic factor by rheumatoid synovial fibroblast 
cells. Transcripts for the EP~ and EP 2 subtypes of PGE receptors 
are expressed in synovial fibroblasts. Activators of protein kinase 
A pathway stimulated the expression of VEGF whereas down- 
regulation of protein kinase C did not influence the PGE effect, 
suggesting that signalling from the EP2 receptor via the protein 
kinase A pathway is important. The induction of VEGF expres- 
sion by PGE 2 and interleukin-I a may be an important mechanism 
in inflammatory angiogenesis. 
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1. Introduction 
Angiogenesis  the process by which new blood vessels grow 
by sprouting from established ones. Blood vessel growth occurs 
during embryonic development but rarely in the adult. How- 
ever, angiogenesis is important in the female reproductive sys- 
tem, in wound healing and in pathological processes uch as 
solid tumor development and rheumatoid arthritis (RA) [1]. 
RA is characterized by pronounced tumor-like xpansion of the 
synovium, primarily because of exuberant proliferation of syn- 
oviocytes and blood vessels [2]. RA synovial tissue, which is 
rich in blood vessels, invades the periarticular cartilage and 
bone and thus destroys the joint. Angiogenesis  an important 
component of chronic synovitis, and its regulation is thought 
to be driven by local production of angiogenic factors such as 
fibroblast growth factor and vascular endothelial growth factor 
(VEGF) [4]. In addition, inflammatory mediators uch as inter- 
leukin-I (IL-1), tumor necrosis factor-c~, IL-8 and prosta- 
glandins (PG) also are involved in the induction of the angio- 
genic response [3,4]. 
The synthesis of prostaglandins is initiated by the cyclooxy- 
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genase-catalyzed oxidation of arachidonic acid into prosta- 
glandin H 2 [5]. The main products of the cyclooxygenase path- 
way, namely prostaglandin E2, (PGE2), prostaglandin F2~, 
thromboxane A2 and prostacyclin are produced by rheumatoid 
synovial tissues [6]. PGE> may play a key role in the erosion 
of cartilage and juxtaarticular bone [7,8]. PGE2 but not PGF2~ 
was shown to induce the angiogenic response [9], but the mech- 
anisms by which prostaglandins induce angiogenesis are not 
understood. 
IL-1 is a primary inflammatory cytokine produced by a vari- 
ety of cells such as monocytes, fibroblasts and endothelial cells 
[10]. Systemic levels of IL-1 have been found to correlate with 
RA disease activity [11]. Injection of IL-1 into joints can induce 
inflammatory synovitis [12]. The majority of IL-I is produced 
by macrophages present in inflamed rheumatoid synovia; how- 
ever, synovial fibroblasts can also synthesize IL-1 [13]. In syn- 
ovial fluid and peripheral blood of patients with RA, prosta- 
glandins are formed as a result of the proinflammatory effects 
of Ik-1 [14,15]. 
VEGF is a family of proteins which are specific endothelial 
mitogens in vitro [16]. Members of the VEGF family were 
discovered because they are potent inducers of microvascular 
permeability, a process important in inflammation [17]. Anti- 
genic VEGF was significantly increased in RA and cells ex- 
pressing VEGF were localized to the RA synovial ining layer 
and subsynovial macrophages [18]. This result suggests a role 
for VEGF in RA-associated angiogenesis. Recently, PGE 2 was 
shown to induce VEGF expression i  osteoblast cells in culture 
[19]. Hyperplastic connective tissues are comprised primarily of 
fibroblasts-like cells and new blood vessels [20,21] and, vessels 
growth is directly proportional to total fibrovascular growth 
[22]. We investigated the possibility that PGE 2 may induce 
angiogenesis in RA synovium by inducing VEGF expression. 
Here we report that PGE,  PGE2 and IL-1 induce the expres- 
sion of VEGF in RA synovial fibroblasts. 
2. Materials and methods 
2.1. Materials 
Materials were obtained from Sigma Chemical Co. unless otherwise 
indicated, 
2.2. RNA isolation and Northern blot analysis 
Synovial fibroblasts from RA patients were isolated as previously 
described [23]. Growth medium is Dulbecco's modified Eagle's medium 
(Mediatech) supplemented with 10% fetal calf serum (HyClone), 10% 
human AB serum (Sigma) and antibiotics: penicillin (100 U/ml), strep- 
tomycin (100 U/ml) and fungizone (0.25 /tg/ml) (JRH Biosciences). 
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Cells were plated in 75 cm 2 flask (Costar) and were allowed to reach 
95% confluency (7 days), then harvested with trypsin (JRH Biosciences) 
and passaged 1:3. Cells were used between the third and the tenth 
passages. Before experiments, a 75 cm 2 flask (95% confluency) was split 
1 : 5 and plated in I00 x 20 mm tissue culture dish (Falcon) with 10 ml 
growth medium. Medium was changed at day 3 and 5 after plating, 
experiments were conducted on the 8th day. Total RNA was isolated 
by the method of Chornczynsky and Sacchi [24], by using Trizol Rea- 
gent (Life Technologies). RNA (I 0 pg) was electrophoresed through 1% 
agarose gel containing 2.2 M formaldehyde and the integrity of the 
RNA analyzed by ethidium bromide staining. The RNA was then 
transferred onto zeta-probe membranes (Bio-Rad) and cross-linked by 
UV light (Stratalinker, Stratagene). The 0.6 kb cDNA of human VEGF 
consisting of the entire coding region for the precursor of the 165- 
residue form (a generous gift from Dr. J, Abraham, Scios Nova Inc.) 
was labeled to high specific activity using [c~-32p]dCTP and a random 
primer labelling system (Rediprime, Amersham). Filters were hybrid- 
ized and washed according to Church and Gilbert's protocol [25]. The 
bands were visualized by autoradiography. 
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR) 
Total RNA (1 ¢tg) was converted to cDNA by incubation at 37°C 
for 1 h in reverse transcriptase buffer (50 mM Tris-HC1, pH 8.3, 75 mM 
KCI, 3 mM MgCI2, 10 mM dithiothreitol), 400 units of Moloney- 
murine leukemia virus reverse transcriptase (Life Technologies Inc.), 40 
units of RNAsin (Promega Corp.), 0.4 mM dNTPs, and 120 ng of 
random hexamers (Pharmacia LKB Biotechnology Inc.). The cDNA 
was diluted to 250 fll and RT-PCR was performed using 5 pl of diluted 
cDNA in 50 pl of 10 mM Tris-HC1, pH 8.3, 50 mM KCI, 0.25 mM 
dNTPs, 1.5 mM MgC12, 0.5/tg of sense and antisense primers and 2.5 
units of Taq polymerase (Boehringer-Mannheim). Samples were ampli- 
fied for 40 cycles of PCR reaction in which denaturation was done for 
1 min at 94°C and extensions was for 3 rain at 72°C. Annealing time 
was 2 min however, the annealing temperature was 55°C for VEGF 
transcript, 59°C for EP~, and 64°C for EP2, EP3, and EP 4. Amplified 
cDNAs were analyzed by 1.4% agarose gel electrophoresis with visual- 
ization by ethidium bromide staining. The primers to the human VEGF 
flanked the variable (carboxyl-terminal) portion of the coding re- 
gions [26]. The sense primer was GAGTGTGTGCCCACTGAGGA- 
GTCCAAC, the antisense primer was CTCCTGCCCGGCTCACC- 
GCCTCGGCTT. The primers to the human prostaglandin receptor 
EPI are: sense primer --- TCTACCTCCCTGCAGCGGCCACTG (nu- 
cleotides 97~999), antisense primer = GAAGTGGCTGAGGCCGC- 
TGTGCCGGGA (nucleotides 1179-1206) [27]. The primers to the 
human prostaglandin receptor EP2 were chosen according to Regan et 
A 
al. [28]: the sense primer was CTTACCTGCAGCTGTACG (nucleo- 
tides 740-757), and the antisense primer was GATGGCAAAGACC- 
CAAGG (nucleotides 109(~ 1107). The primers to human EP3I receptor 
were chosen according to Adam et al. [29]: the sense primer was GAG- 
CACTGCAAGACACACACGGAG (nucleotides 937-960), the anti- 
sense primer was GATCTCCATGGGTATTACTGACAA (nucleotides 
1312-1335). The primers to human EP4 were chosen according to 
Bastien et al. [30]: the sense primer was CTGGCGATCAACCATG- 
CCTATTTC (nucleotides 742-765) and the antisense primer was 
TGAGCACCACCAGGGAGGTGGCAAAAT (nucleotides 1209 
1236). 
3. Resu l ts  
3.1. IL - la ,  PGE2 and PGE 1 #lduce VEGF expression 
Prostaglandins are important mediators of inflammation in 
RA [31,32]. IL-1 is a major proinflammatory cytokine present 
in synovial fluid and peripheral blood of RA patients. Because 
both agents have been implicated in inflammatory angiogene- 
sis, we investigated the effects of PGE~, PGE2 and IL-1 on the 
induction of VEGF expression in RA synovial fibroblasts. The 
results obtained show that PGE2, PGE~ (1 pM)  and IL- I~ (10 
ng/ml) induce a single VEGF transcript of approximately 3.8 
kb (Fig. 1A). Induction of VEGF is specific to prostaglandin 
El and E 2 since no induction was observed in prostaglandin 
F2~-treated cells. In addition, the VEGF transcript in human 
foreskin fibroblasts was not induced by PGE2 whereas phorbol 
12-myristate 13-acetate and COC12 was capable of inducing it 
(data not shown). Four isoforms of VEGF coding regions have 
been described. A cDNA clone encoding a 189-amino-acid 
form of human VEGF (VEGFt89) has been isolated from U-937 
cells [33]. cDNAs clones encoding VEGFIs 9 and 165-and 121- 
amino acid forms of human VEGF (VEGFI65 and VEGF~21, 
respectively) was isolated from phorbol ester-activated HL60 
cells [34]. Another isoform of VEGF, 206 amino acids in length 
(VEGF206) was found in fetal liver library [35]. To investigate 
the occurrence of the VEGF coding region heterogeneity in
synovial fibroblasts, we used RT-PCR with primers flanking 
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Fig. 1. Induction of VEGF expression i  RA synovial fibroblasts. (A) Confluent monolayers of RA synovial fibroblasts were treated with 1 ,uM of 
PGE I (E0, prostaglandin F2~ (PGF) and PGE 2 (E2) for 1 h, or with 10 ng/ml IL-I or 100pM COC12 for 20 h, or maintained under normal conditions 
(NT). Total RNA (10,ug) was analyzed by Northern blot utilizing a VEGF~65 radiolabeled probe. The locations of 28S and 18S rRNA are indicated. 
Autoradiographic were exposure is for 2 days. (B) Confluent monolayers of synovial fibroblasts were maintained under normal conditions (NT), 
or exposed for 6 h to 100 ng/ml phorbol 12 myristate 13-acetate (PMA). RNA (1 pg) was converted to cDNA and RT-PCR with the primers to the 
human VEGF was performed. PCR reaction in the absence of RT (H20) served as negative control. 
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Fig. 2. Time-course of VEGF expression i response to PGE,. Conflu- 
ent monolayers of synovial fibroblasts were treated with PGE~ (1/IM) 
for the indicated times or, maintained under normal conditions (NT). 
Total RNA (10 ,ug) was analyzed by Northern blot utilizing a VEGF165 
radiolabeled probe. The locations of 28S and 18S rRNA are indicated. 
Autoradiographic exposure is for 2 days. 
the VEGF variable (carboxyl-terminal) portion [26]. RNA was 
extracted from synovial fibroblasts treated with phorbol 12- 
myristate 13-acetate (100 ng/ml, 6 h) and RT-PCR reaction was 
performed as described in section 2. The expected sizes of the 
PCR products are 435, 384, 312, and 180 for VEGF206, 
VEGF~89, VEGFI65 and VEGF12 L, respectively. In control un- 
treated cells, the analysis revealed a minute presence of two 
bands of 312 and 384 bp corresponding to VEGF~65 and 
VEGF~89, respectively. In phorbol 12-myristate 13-acetate- 
treated cells however, there was a marked elevation in VEGF165 
and VEGF189 as well as induction of a band of 180 bp, corre- 
sponding to VEGFI21 (Fig. 1B). 
The kinetics of VEGF expression was determined at 15-20 
h after treating the cells with PGE~ and PGE 2 and, 548 h after 
treating the cells with 1L-1. Treatment of synovial fibroblasts 
with 10 -6 M PGE~ resulted in transient increase in the level of 
VEGF mRNA which peaked at 60 min and declined within 3 h 
(Fig. 2). In contrast to the rapid response of the cells to prosta- 
glandins, IL-lc~ induced an elevation in VEGF mRNA only 
after 8 h; this effect, however, was sustained up to 48 h (Fig. 
3A). IL-1 is a potent and sustained inducer of PG synthesis by 
up-regulation of Cox-2 expression [41]. To determine if IL-1- 
induced PGE2 is involved in the VEGF induction, RA synovial 
fibroblasts were treated with IL-I~ in the presence of in- 
domethacin, an inhibitor of the cyclooxygenase activity [6], As 
shown in Fig. 3B, IL-1 induction of VEGF was not blocked by 
indomethacin, ruling out the involvement of autocrine PGE~ 
action. 
3.2. Signal transduction mechanisms involved in PGE induction 
of VEGF transcript 
PGEj or PGE2 mediates its action via interaction with four 
pharmacologically defined subtypes of prostaglandin receptors 
[27-30]. All these subtypes display high affinity for PGE 2 but 
show differences in their affinities for various agonists and 
antagonists and exert their actions through different signal 
transduction mechanisms. Thus activation of the EP~ receptor 
has been associated with a rise in intracellular calcium [27], 
activation of the EP2 and EP 4 receptors with increases in intra- 
85 
cellular cAMP [28,30], respectively, and activation of the EP 3 
receptor with a decrease in intracellular cAMP [36,37]. Identifi- 
cation of the coupling mechanisms between the prostaglandin 
receptors and the intracellular components requires the initial 
identification of the cellular receptor subtype. To this end, 
cDNA from synovial fibroblasts was amplified with four dis- 
tinct receptor-specific oligonucleotide primers. Amplified prod- 
ucts of human EP~ and EP2 were observed (Fig. 4) without 
detection of either EP3 or EP4. Adenylate cyclase and/or phos- 
pholipase C/protein kinase C pathways might therefore be in- 
volved in the induction of VEGF transcription by PGE2. 
To further investigate the signalling mechanisms, RA syno- 
vial fibroblasts were treated with PGE 2 in the presence or the 
absence of cholera and pertussis toxins, which modulate the 
activities of the Gs and the G~ proteins, respectively. Treatment 
with pertussis toxin did not influence the PGE effect, suggesting 
that the EP3/G ~ pathway is not involved. However, cholera 
toxin and forskolin, agents that activate the intracellular cAMP 
28~ 
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18S 
28S 
a 
NT 
28S - 
INDO IL-1 IL-1, Indo 
18S - 
28S - 
b 
Fig. 3. Induction of VEGF expression by IL-1. (A) Confluent monolay- 
ers of synovial fibroblasts were treated with IL-I (10 ng/ml) for the 
indicated times or maintained under normal conditions (NT). Total 
RNA (10 ,ug) was analyzed by Northern blot utilizing a VEGFj65 
radiolabeled probe. The locations of 28S and 18S rRNA are indicated. 
Autoradiographic exposure is for 2 days. (B) Confluent monolayers of 
synovial fibroblasts were treated with IL-1 (10 ng/ml), indomethacin (2
pM) or the combination of IL-1 and indomethacin for 20 h or, main- 
tained under normal conditions (NT). Total RNA (10/tg) was analyzed 
by Northern blot utilizing a VEGF~65 radiolabeled probe. Autoradi- 
ographic exposure is for 2 days. 
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Fig. 4. Detection of the prostaglandin receptors in synovial fibroblasts. 
RNA (1 pg) from confluent monolayers of synovial fibroblasts was 
converted to cDNA. RT-PCR reaction with the primers to the human 
EP~, EP2 and EP 4 was performed. -=  minus reverse transcriptase 
control. 
levels potently activated the VEGF mRNA levels. (Fig. 5A). 
This suggests that EPJGJcAMP/protein kinase-A pathway is 
involved in the VEGF induction by PGE 2. To further investi- 
gate the possible influence of protein kinase-C, a major sig- 
nalling pathway activated by EP1 subtype of receptors, RA 
synovial fibroblasts were treated with phorbol myristic acetate 
(PMA) for 16 h to down-regulate he intracellular protein ki- 
nase C. Whereas PMA was able to upregulate VEGF expres- 
sion in control cells, down-regulated cells did not respond to 
PMA treatment for 6 h. However, PGE2 was able to activate 
VEGF expression in protein kinase-C down-regulated cells, 
suggesting that EPl/Gq/phospholipase C/protein kinase C path- 
way is not involved in the PGE induction of VEGF expression 
(Fig. 5B). 
A 
4. Discussion 
Spatially- and temporally-regulated formation of new blood 
vessels is required for the development and repair of all tissues. 
Angiogenesis involves the proliferation, migration and differen- 
tiation of endothelial cells and is regulated by polypeptide 
growth factors. VEGF is the only well-characterized secreted 
mitogenic factor which acts exclusively on endothelial cells [38]. 
In a mouse model of proliferative r tinopathy, it was found that 
VEGF is expressed in the retina prior to the development of
neovascularization, suggesting that it is a primary angiogenic 
factor [39]. 
While PGEt and PGE2 are potent inducers of angiogenesis 
in vivo [9], their mechanism of action is unknown. PGEI and 
PGE2 do not directly stimulate angiogenesis in vitro on endo- 
thelial cells (unpublished results). High levels of prostaglandins 
are produced by RA synovia and dysregulated angiogenesis is 
a major feature of the pathology of this chronic inflammatory 
process [8,9]. We therefore investigated whether PGE~ and 
PGE2 induced the VEGF expression by RA synovial fibro- 
blasts. The results obtained emonstrate hat PGEj, PGE2 and 
IL-lc~ induce the expression of VEGF in synovial fibroblasts, 
albeit with different kinetics. Interestingly, PGE2 did not induce 
VEGF mRNA in human foreskin fibroblasts. Cell-type specific 
regulation of VEGF expression by PGE 2 could be related to the 
presence or absence of relevant PGE 2 receptor subtypes. Re- 
cently, it was shown that IL-lfl induces VEGF in rat aortic 
smooth muscle cells [40]. IL-1 also induces the sustained synthe- 
sis of prostaglandins via induction the transcriptional induction 
and stabilization of the mRNA for the enzyme cyclooxygenase- 
2 [41]. Because indomethacin did not block the ability of IL-l 
to induce VEGF expression, it is unlikely that autocrine stimu- 
lation by PGE 2 is involved. However, indomethacin does not 
B 
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28S 
28S 
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Fig. 5. Signalling mechanisms in PGE induction of VEGF mRNA. (A) Confluent monolayers of synovial fibroblasts were treated with PGE 2 (1 pM), 
forskolin (10 pM), pertussis toxin (pertussis) (20 ng/ml), cholera toxin (cholera) (50 ng/rnl), or the combination of PGE2 with forskolin, pertussis 
toxin and cholera toxin for 1 h, or, maintained under normal conditions (NT). Total RNA (10,ug) was analyzed by Northern blot utilizing a VEGF~65 
radiolabeled probe. Autoradiographic exposure is for 2 days. (B) Confluent monolayers of synovial fibroblasts were treated with PGE2 (1/.tM) for 
1 h, PMA (100 ng/ml) for 6 h or, maintained under normal conditions (NT). Pretreatment of the cells with 100 ng/ml PMA for 16 h was used as 
a procedure to down-regulate PKC. Cells were then treated with PGE2 for 1 h or with PMA for 6 h or, without any further addition. Total RNA 
(10/zg) was analyzed by Northern blot utilizing a VEGFj65 radiolabeled probe. Autoradiographic exposure is for 2 days. 
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block the peroxidase activity of Cox-2 and other IL-1-inducible 
genes which may be important. 
PGE2, which is a potent stimulator of angiogenesis [9], in- 
duces a rapid induction of VEGF mRNA in synovial fibro- 
blasts. We also found that RA synovial fibroblasts express the 
prostaglandin receptors, EP1 and EP2. Various prostaglandin 
receptors were found in human erythroleukemia cell line [42]. 
EP 1 elevates intracellular Ca 2~ levels in injected Xenopus 
oocytes [27] probably due to coupling phospholipase C. EP 2 
stimulates the formation of cAMP in EP2-transfected Cos-7 
cells [28]. Because forskolin and cholera toxin also stimulated 
VEGF expression and because down-regulation of protein ki- 
nase C is not important for the PGE induction of VEGF 
mRNA,  EPz/G]adenylate cyclase/protein kinase-A may be an 
important signalling pathway in RA synovial fibroblasts. In- 
duction of VEGF by protein kinase A and protein kinase C 
pathways was also observed in osteoblasts [19] and preadi- 
pocytes [43]. 
IL-1, PGE2 and PGEL but not PGF2~ strongly stimulate the 
expression of VEGF in RA synovial fibroblasts. Since these 
agonists are capable of inducing angiogenesis [9,44,45], the 
induction of VEGF may be an important mechanism in inflam- 
matory angiogenesis. Pharmacologic modulation of this path- 
way may be potentially useful in controlling RA. 
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